Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the overall survival analysis of the LUX-Lung 3 and LUX-Lung 6 trials.
Over the past several years, 7 trials have examined erlotinib and gefitinib compared with chemotherapy for the treatment of lung cancer patients with EGFR
mutations. These studies have all shown progression-free survival (PFS) and objective response benefit with the EGFR inhibitors.
Sequist says the PFS data from LUX-Lung 3 and LUX-Lung 6 led to the approval of afatinib in many countries. Identical results were seen between the two studies — there was no survival advantage between afatinib and chemotherapy, though patients with different EGFR
mutations experienced varying degrees of benefit.
<<< View more from the 2014 Multidisciplinary Symposium in Thoracic Oncology